2143-93-3

Usage

Uses

Used in Pharmaceutical Industry:
3-(E)-(TRIFLUOROMETHYL)CINNAMIC ACID is used as a building block for the synthesis of various pharmaceuticals due to its unique chemical structure and potential biological activities, including anti-inflammatory, anti-cancer, and antimicrobial properties.
Used in Agrochemical Industry:
3-(E)-(TRIFLUOROMETHYL)CINNAMIC ACID is used as a precursor in the development of agrochemicals, leveraging its chemical properties to create compounds with potential applications in crop protection and enhancement of agricultural yields.
Used in Materials Science:
3-(E)-(TRIFLUOROMETHYL)CINNAMIC ACID is utilized in the synthesis of novel materials, taking advantage of its chemical reactivity and structural features to engineer materials with specific properties for various applications.
Used in Organic Synthesis:
3-(E)-(TRIFLUOROMETHYL)CINNAMIC ACID is employed as an intermediate in organic synthesis, contributing to the creation of complex organic molecules for a wide range of applications across different industries.

InChI:InChI=1/C10H7F3O2/c11-10(12,13)8(6-9(14)15)7-4-2-1-3-5-7/h1-6H,(H,14,15)/b8-6-

Upstream product

• 56210-75-4 ethyl (2Z)-3-trifluoromethyl-3-phenylprop-2-enoate 
• 434-45-7 2,2,2-Trifluoroacetophenone 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 10075-06-6 ethyl 3-phenyl-4,4,4-trifluoro-2-butenoate (E,Z) 

Downstream Products

• 197443-23-5 (Z)-3-phenyl-4,4,4-trifluoro-2-butenoyl chloride 

Relevant academic research and scientific papers

Visible-light promoted oxidative cyclization of cinnamic acid derivatives using xanthone as the photocatalyst

We have developed an efficient photocatalytic synthesis of coumarin derivativesviaa tandem double bond isomerization/oxidative cyclization of cinnamic acids. Inexpensive and stable xanthone was used as the photocatalyst, and readily available Selectfluor was used as the oxidant. This method tolerates a wide range of functional groups and offers excellent chemical yields in general. Besides, the photocatalytic oxidative cyclization of cinnamic acid esters gives dimerized lignan-type products.

INHIBITORS OF BETA AMYLOID PRODUCTION

Novel sulfonamide compounds useful in the treatment of conditions related to the production of beta-amyloid are described, as are routes to their preparation. The sulfonamide compounds are of the following structure, wherein R1-R3 are defined herein. Also provided are pharmaceutical compositions containing these compounds and/or prodrugs of these compounds and a physiologically compatible carrier. These compounds are specifically useful for inhibiting beta amyloid production, and treating Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome.

Synthesis of cytotoxic fluorinated quassinoids

The C-15 senecioyl side chain of brusatol was interchanged with fluorinated acyl groups, and the C-3 hydroxy group of bruceolide was esterified with fluorinated acyl chlorides. These fluorinated quassinoids 11, 12, 13, and 17 showed significant cytotoxic activity against eight human cancer cell lines including small and non-small cell lung, colon, CNS, ovarian and renal cancers, leukemia, and melanoma with 17 being about 100 times more potent than 11, 12, and 13. The activity of 17 was similar to that of bruceantin (1) in this in vitro cell line panel.

Synthesis and Structure-Activity Relationships of 1-Acyl-4-(2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF Antagonists

A second generation of (cyanomethyl)piperazines, 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines, with increased oral activity was prepared and evaluated in vitro in PAF-induced platelet aggregation assay (PAG) and in vivo in a PAF-induced hypotension test in normotensive rats (HYP).Oral activity was ascertained through a PAF-induced mortality test in mice (MOR).Attachment of a methyl group at position 2 of our earlier pyridine derivatives resulted in an improvement of 1 order of magnitude or greater in the ID50 of the oral test.Three different types of acylsubstituents of similar potency emerge from this work: N-(diphenylmethylamino)acetyl, 3-substituted 3-hydroxy-3-phenylpropionyl, and N-substituted 3-amino-3-phenylpropionyl groups.The most interesting compounds, 26 (UR-12460, PAG IC50 = 0.040 μM, HYP, ID50 = 0.021 mg/kg iv, MOR, ID50 = 0.30 mg/kg po) and 58 (UR-12519, PAG IC50 = 0.041 μM, HYP, ID50 = 0.015 mg/kg iv, MOR, ID50 = 0.044 mg/kg po), compare favorably with WEB-2086.Compounds 26 and 58 were also tested in active anaphylactic shock (AAS) and endotoxin-induced mortality (EIM) tests.On the basis of these data, compounds 26 and 58 have been selected for further pharmacological development.

(2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists

The present invention relates to new (2-alkyl-3-pyridyl) methylpiperazine derivatives of general formula I: wherein R1, R2 and Z are as defined in Claim 1. The invention also relates to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent, orally active PAF antagonists and, consequently, they are useful in the treatment of the diseases in which this substance is involved.